Perhaps your weight has changed while your routine feels much the same. Perhaps you have tried several approaches and want to understand whether medicine could help. This guide puts the questions in order: medical suitability, everyday meals, activity, costs and support over time.

Why take a closer look after 40?

Working patterns, sleep, movement and body composition can change over the years. Menopause may add further questions. Reducing everything to one explanation, such as hormones, can miss what is actually happening. The useful starting point is your own timeline, symptoms and existing health conditions.

Write down whether stairs feel harder, your sleep has changed or thoughts about food occupy more of your day. These observations can make your goals more meaningful than a particular number on the scales. Being over 40 does not by itself establish a medical reason for treatment.

What medicine can change

GLP-1-based medicines influence processes including appetite and fullness. Some people find it easier to eat less without feeling the same intensity of hunger. This does not remove the need for adequate nutrition or an individual assessment. Medicine also cannot automatically resolve stress, difficult working hours or distress about appearance.

In the EU, certain products are authorised for obesity or for overweight accompanied by weight-related health problems. A clinician assesses suitability in the context of your whole health picture. An online comparison or BMI calculator cannot make that decision.

An injection or tablet involves more than preference

Wegovy is now authorised in the EU in both injectable and tablet forms. Mounjaro contains a different active ingredient. Each form has its own instructions. Taking several morning medicines, working shifts or travelling frequently creates different practical questions from having a predictable daily routine.

Authorisation does not mean every form is immediately available or reimbursed in every country. Check both the country and date of an availability claim. Changing products is a clinical discussion and should not follow directly from a price comparison.

What a workable treatment plan includes

Look for understandable goals, a named contact for problems and agreed follow-up. Discuss how to maintain varied, adequate meals if your appetite becomes smaller. Strength, physical function and wellbeing deserve attention alongside weight. WHO places medicines within comprehensive obesity care.

Bring up your budget early. Ask about the full ongoing cost, any additional appointments and what would happen if health problems or finances prevented you from continuing. An expensive commitment made under pressure is a poor foundation for a long-term decision.

Choose a useful starting point

If you are exploring treatment, begin with the explanation of GLP-1 and GIP and the appointment preparation guide. If you already have a prescription, the pages about meals, symptoms and daily routines may be more immediately useful. For costs, the relevant healthcare system matters more than the language of a website.

Severe new symptoms are not a reason to keep browsing general advice. Persistent severe abdominal pain, breathing difficulties or sudden deterioration in vision need prompt medical attention. A website comment section cannot provide urgent assessment.

Common questions

Should I choose a product before seeing a clinician?

No. Bring your questions, previous experiences and a complete medicines list. Product selection follows assessment and a discussion of the available options.

Does needing medicine mean I have failed?

Treatment is not a judgement about willpower. You can accept support while deciding which approach fits your health, priorities and everyday circumstances.

Explore all 100 topics

The basics and recent developments

Preparing for treatment

Costs, access and safety

Understanding symptoms

Food and drink

Strength and movement

Life stages and other conditions

Everyday life and body confidence

Long-term planning and checking claims

Practical tools

Sources & further reading

  1. EMA: Wegovy – EPAR und Produktinformation
  2. EMA: Mounjaro – EPAR und Produktinformation
  3. WHO: GLP-1 therapies for obesity, 1 December 2025

Sources checked:

eu. infopoint editorial team

Researched and created with AI assistance. This article has not undergone individual review by a medical professional.

About our health information

Published:

Report a correction

Questions and experiences

Share a question or a useful experience about this topic. Every contribution is checked before publication. Comments may be written in different languages.

Loading reader contributions…

Opening the form sets a necessary session cookie. No email address is required. Publication is subject to moderation and is not guaranteed. For deletion requests: Contact